NanoViricides (NYSE:NNVC) Stock Price Up 5% – Still a Buy?

Shares of NanoViricides, Inc. (NYSE:NNVC) traded up 5% during trading on Friday . The stock traded as high as $1.05 and last traded at $1.05. 207,916 shares traded hands during mid-day trading, a decline of 26% from the average session volume of 280,936 shares. The stock had previously closed at $1.00.

Wall Street Analysts Forecast Growth

Separately, Alliance Global Partners started coverage on NanoViricides in a report on Tuesday, December 16th. They set a “buy” rating on the stock. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, NanoViricides has a consensus rating of “Buy”.

NanoViricides Stock Performance

The firm has a market capitalization of $22.67 million, a price-to-earnings ratio of -1.46 and a beta of 1.32. The business has a fifty day moving average price of $1.09 and a 200 day moving average price of $1.31.

Institutional Trading of NanoViricides

A number of institutional investors have recently modified their holdings of the company. Armistice Capital LLC purchased a new position in NanoViricides in the fourth quarter valued at approximately $1,546,000. Geode Capital Management LLC increased its position in shares of NanoViricides by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 174,371 shares of the company’s stock worth $197,000 after acquiring an additional 14,944 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of NanoViricides in the 4th quarter valued at $140,000. Susquehanna International Group LLP lifted its holdings in shares of NanoViricides by 37.4% during the 3rd quarter. Susquehanna International Group LLP now owns 52,217 shares of the company’s stock valued at $75,000 after acquiring an additional 14,217 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of NanoViricides by 29.4% during the 4th quarter. State Street Corp now owns 54,206 shares of the company’s stock valued at $61,000 after acquiring an additional 12,300 shares in the last quarter. Hedge funds and other institutional investors own 10.30% of the company’s stock.

NanoViricides Company Profile

NanoViricides, Inc is a clinical-stage biotechnology company focused on the development of novel antiviral therapies using its proprietary nanomicelle technology. The company designs polymeric, virus-targeted nanoviricides that seek to neutralize viral pathogens by binding to specific viral surface proteins and destroying their structural integrity. NanoViricides’ platform is intended to offer broad-spectrum activity against a range of enveloped viruses, positioning it as a potential solution for both existing and emerging viral threats.

The company’s pipeline includes preclinical and early clinical candidates targeting seasonal and pandemic influenza strains, as well as investigational programs for coronaviruses, hepatitis, dengue, HIV and other viruses.